Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI has entered into an agreement to acquire cancer test manufacturer Personalis for $1.5 billion, triggering a decline in both companies' share prices.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Tempus AI is acquiring the cancer genomics company Personalis in a transaction valued at $1.5 billion. The deal is intended to integrate Personalis’ molecular residual disease technology into the existing AI-enabled precision oncology platform operated by Tempus.
Coverage from Reuters, Fierce Biotech, Business Wire, Barron's, and Investor's Business Daily highlights the acquisition agreement and the immediate market reaction. Reports confirm that shares for both companies fell following the announcement.
Future updates will track the completion of the integration process and any subsequent shifts in the companies' stock performance. Coverage does not yet specify a finalized date for the transaction to close.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 16h ago.
Quick answers
What is the total value of the acquisition?
The acquisition is valued at $1.5 billion.
What is the stated purpose of the deal?
The deal aims to integrate Personalis' molecular residual disease technology into Tempus AI’s precision oncology platform.
How did the stock market react to the announcement?
Shares for both Tempus AI and Personalis declined following the news.
Coverage (7)
- Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal qz.com · 17h ago
- Tempus AI to Buy Cancer-Tech Firm Personalis For $1.7 Billion Bloomberg.com · 17h ago
- Tempus buys out cancer genomics partner Personalis in $1.5 billion deal Fierce Biotech · 21h ago
- Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Business Wire · 21h ago
- Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink Barron's · 21h ago
- Tempus to buy cancer test maker Personalis for $1.5 billion Reuters · 21h ago
- Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive Investor's Business Daily · 21h ago
Topics
Related trends
Exclusive | Icahn to Sell Auto-Service Chain Pep Boys to Mavis for $700 Million
Icahn Enterprises has reached an agreement to sell its auto-service chain, Pep Boys, to Mavis Tire in a deal valued at $700 million.
Brookfield and CPP Investments to Buy LXP Industrial for $5.2 Billion
Brookfield and CPP Investments have reached an agreement to acquire LXP Industrial Trust in an all-cash transaction valued at $5.2 billion.
Leading oncologist reveals 6 habits that could promote longevity and reduce your risk of chronic illness
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
An experimental KRAS-targeted vaccine has demonstrated a safe, durable immune response in individuals at high risk for pancreatic cancer.
Uber to buy Germany’s Delivery Hero in $14.8bn global deal
Uber Technologies has announced an agreement to acquire Germany-based Delivery Hero in a deal valued at approximately $14.8 billion.
Banijay and Mediawan Eye Lionsgate Studios Takeover
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.